FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213078613> ?p ?o ?g. }

• W4213078613 endingPage "870" @default.
• W4213078613 startingPage "853" @default.
• W4213078613 abstract "A post hoc, descriptive analysis of three prospective, randomised, controlled clinical studies investigating cefiderocol in gram-negative bacterial infections was conducted to assess its efficacy in patients with baseline bacteraemia.Data from APEKS-cUTI (NCT02321800), APEKS-NP (NCT03032380) and CREDIBLE-CR (NCT02714595) studies were assessed individually. Patients received cefiderocol 2g, q8h, for 7-14 days or comparators (imipenem/cilastatin [APEKS-cUTI], meropenem [APEKS-NP] or best available therapy [BAT; CREDIBLE-CR]). Bacteraemia and clinical outcomes were assessed at early assessment (EA), end of treatment (EOT) and test of cure (TOC) for patients in the intention-to-treat populations with baseline blood samples positive for aerobic gram-negative species. Eradication, persistence or recurrence of baseline blood pathogen was confirmed from follow-up blood cultures; in the absence of follow-up blood cultures, clinical response, administration of additional antibiotics and vital status were used to assess bacteraemia outcome.Of 885 patients randomised, 84 had bacteraemia and 89 (cefiderocol: 55, comparators: 34) gram-negative pathogens were isolated, namely Enterobacterales (n = 62) and non-fermenters (n = 27). At EA, on-therapy bacteraemia eradication rates in APEKS-cUTI, APEKS-NP and CREDIBLE-CR were 100% (19/19), 50.0% (4/8) and 72.0% (18/25) with cefiderocol. Corresponding rates for comparators were 77.8% (7/9), 100% (10/10) and 69.2% (9/13), respectively. Persistence in blood at EA was seen in six patients overall (cefiderocol: 3, comparators: 3); indeterminate responses were common (cefiderocol: 8, comparators: 3), usually due to lack of blood cultures. Clinical cure/improvement rates at EA in APEKS-cUTI, APEKS-NP and CREDIBLE-CR were 100% (19/19), 62.5% (5/8) and 64.0% (16/25) with cefiderocol. Corresponding rates for comparators were 77.8% (7/9), 90.0% (9/10) and 30.8% (4/13), respectively. Bacteraemia eradication rates with cefiderocol in APEKS-cUTI, APEKS-NP and CREDIBLE-CR were 89.5%, 37.5% and 60.0% at EOT and 78.9%, 12.5% and 44.0% at TOC.This descriptive analysis suggests that cefiderocol may be a useful treatment option for gram-negative bacteraemia, including pathogens resistant to other antibiotics." @default.
• W4213078613 created "2022-02-24" @default.
• W4213078613 creator A5020938031 @default.
• W4213078613 creator A5047147049 @default.
• W4213078613 creator A5047544838 @default.
• W4213078613 creator A5050331950 @default.
• W4213078613 creator A5058005775 @default.
• W4213078613 date "2022-02-20" @default.
• W4213078613 modified "2023-09-30" @default.
• W4213078613 title "Outcomes with Cefiderocol Treatment in Patients with Bacteraemia Enrolled into Prospective Phase 2 and Phase 3 Randomised Clinical Studies" @default.
• W4213078613 cites W2338445208 @default.
• W4213078613 cites W2520003227 @default.
• W4213078613 cites W2604646349 @default.
• W4213078613 cites W2683046555 @default.
• W4213078613 cites W2741262638 @default.
• W4213078613 cites W2766395453 @default.
• W4213078613 cites W2883234304 @default.
• W4213078613 cites W2884843951 @default.
• W4213078613 cites W2898144230 @default.
• W4213078613 cites W2899757291 @default.
• W4213078613 cites W2904708694 @default.
• W4213078613 cites W2965928198 @default.
• W4213078613 cites W2982646971 @default.
• W4213078613 cites W3005700774 @default.
• W4213078613 cites W3007524117 @default.
• W4213078613 cites W3009804497 @default.
• W4213078613 cites W3016139827 @default.
• W4213078613 cites W3019232346 @default.
• W4213078613 cites W3026777707 @default.
• W4213078613 cites W3052770158 @default.
• W4213078613 cites W3080683233 @default.
• W4213078613 cites W3087097003 @default.
• W4213078613 cites W3088003513 @default.
• W4213078613 cites W3090322582 @default.
• W4213078613 cites W3092173712 @default.
• W4213078613 cites W3092383626 @default.
• W4213078613 cites W3093414038 @default.
• W4213078613 cites W3093763072 @default.
• W4213078613 cites W3112514538 @default.
• W4213078613 cites W3118267165 @default.
• W4213078613 cites W3118701213 @default.
• W4213078613 cites W3118795389 @default.
• W4213078613 cites W3120878560 @default.
• W4213078613 cites W3151221590 @default.
• W4213078613 cites W3169176269 @default.
• W4213078613 cites W3170785091 @default.
• W4213078613 cites W3179007543 @default.
• W4213078613 cites W3209839356 @default.
• W4213078613 cites W3217749790 @default.
• W4213078613 cites W4200397598 @default.
• W4213078613 cites W4200476099 @default.
• W4213078613 cites W4206012034 @default.
• W4213078613 doi "https://doi.org/10.1007/s40121-022-00598-9" @default.
• W4213078613 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35184255" @default.
• W4213078613 hasPublicationYear "2022" @default.
• W4213078613 type Work @default.
• W4213078613 citedByCount "9" @default.
• W4213078613 countsByYear W42130786132022 @default.
• W4213078613 countsByYear W42130786132023 @default.
• W4213078613 crossrefType "journal-article" @default.
• W4213078613 hasAuthorship W4213078613A5020938031 @default.
• W4213078613 hasAuthorship W4213078613A5047147049 @default.
• W4213078613 hasAuthorship W4213078613A5047544838 @default.
• W4213078613 hasAuthorship W4213078613A5050331950 @default.
• W4213078613 hasAuthorship W4213078613A5058005775 @default.
• W4213078613 hasBestOaLocation W42130786131 @default.
• W4213078613 hasConcept C126322002 @default.
• W4213078613 hasConcept C177713679 @default.
• W4213078613 hasConcept C2779375183 @default.
• W4213078613 hasConcept C2779473907 @default.
• W4213078613 hasConcept C2779631663 @default.
• W4213078613 hasConcept C2781255259 @default.
• W4213078613 hasConcept C501593827 @default.
• W4213078613 hasConcept C71924100 @default.
• W4213078613 hasConcept C86803240 @default.
• W4213078613 hasConcept C89423630 @default.
• W4213078613 hasConcept C94665300 @default.
• W4213078613 hasConceptScore W4213078613C126322002 @default.
• W4213078613 hasConceptScore W4213078613C177713679 @default.
• W4213078613 hasConceptScore W4213078613C2779375183 @default.
• W4213078613 hasConceptScore W4213078613C2779473907 @default.
• W4213078613 hasConceptScore W4213078613C2779631663 @default.
• W4213078613 hasConceptScore W4213078613C2781255259 @default.
• W4213078613 hasConceptScore W4213078613C501593827 @default.
• W4213078613 hasConceptScore W4213078613C71924100 @default.
• W4213078613 hasConceptScore W4213078613C86803240 @default.
• W4213078613 hasConceptScore W4213078613C89423630 @default.
• W4213078613 hasConceptScore W4213078613C94665300 @default.
• W4213078613 hasIssue "2" @default.
• W4213078613 hasLocation W42130786131 @default.
• W4213078613 hasLocation W42130786132 @default.
• W4213078613 hasLocation W42130786133 @default.
• W4213078613 hasOpenAccess W4213078613 @default.
• W4213078613 hasPrimaryLocation W42130786131 @default.
• W4213078613 hasRelatedWork W114029332 @default.
• W4213078613 hasRelatedWork W134274435 @default.
• W4213078613 hasRelatedWork W164198555 @default.
• W4213078613 hasRelatedWork W1983668880 @default.

• next